Key Highlights
- Raised $130M in oversubscribed Series C funding, led by Kinnevik and FPV, bringing total funding to $360M.
- Funding supports delivery of clinical catalysts in 2025 and 2026 and further development of Enveda’s 10 Development Candidates and deep pipeline.
- Enveda’s AI-powered platform leverages metabolomics to identify and characterize over 1 million natural compounds for rapid and differentiated drug discovery.
- Recently entered Phase I clinical trials for ENV-294, targeting atopic dermatitis and inflammatory conditions.
Source: Business Wire
Notable Quotes
- “Some of the world’s greatest pharmaceutical breakthroughs have been derived from just 0.1% of nature’s chemistry. This funding will help us advance multiple candidates to exciting clinical catalysts in the next year.” – Viswa Colluru, Founder and CEO at Enveda
- “Enveda has continually delivered on the promise of its platform with world-class execution, giving us great confidence in the team’s ability to achieve the full potential of their ambitious vision.” – Christian Scherrer, Senior Investment Director at Kinnevik
- “We believe that Enveda is an outstanding and potentially epoch defining company, at the intersection of biology and technology.” – James Anderson, CIO & Managing Partner at Lingotto Innovation
SoHC's Take
Enveda’s successful Series C funding round underscores its leadership in leveraging AI and metabolomics for modern drug discovery. The company’s ability to decode nature’s chemistry at scale sets it apart, ensuring faster development of therapeutics and significant cost reduction. The clearance of ENV-294 for clinical trials and a robust pipeline positions Enveda as a pivotal player in addressing today’s healthcare challenges. This funding marks a critical step forward in their mission to harness life’s evolved solutions for pressing medical needs.
